LG4033D4033   is a selective androgen receptor modulator (SA RMS), and a novel non-steroidal SA RM that binds to AR with high affinity (Ki of ~1 nM) and selectivity. It's in a class of androgen receptor (AR) ligands that is tissue selective, developed to treat muscle wasting associated with cancer, acute and chronic illness and age-related muscle loss. 4033 is expected to produce the therapeutic benefits of tolerability and patient acceptance due to tissue-selective mechanism of action and an route of administration.

LG4033D4033 works by tying androgen receptors selectively
This was an unplanned, double bind analysis stage that included a placebo. The objective was to form that using 4033 was harmless and easy to stomach with a dose not beyond 22 mg a day.

Clinical runs also showed that 4033 has the ability to set off the following benefits when taken consistently:

  1.An increase in strength levels
  2.Lean muscle mass improved
  3.A drop in body fat
  4.Has healing properties
  5.Does not cause the undesirable side effects caused by prohormones.